A new study published in Clinical Rheumatology exposes
how vaccine manufacturers used phony placebos in clinical trials to
conceal a wide range of devastating risks associated with HPV vaccines.
Instead of using genuine inert placebos and comparing health impacts
over a number of years, as is required for most new drug approvals,
Merck and GlaxoSmithKline spiked their placebos with a neurotoxic
aluminum adjuvant and cut observation periods to a matter of months.
